Clinical Development of Selective CDK4/6 Inhibitors: Monotherapy Activity and Mechanisms of Resistance

The second of 3 downloadable slidesets from a satellite symposium at the 2017 annual meeting in Chicago: Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, review critical studies on the clinical and preclinical characteristics of CDK4/6 inhibitors in multiple tumor types.
Format: Microsoft PowerPoint (.ppt)
File Size: 2.79 MB
Released: June 8, 2017


Supported by an educational grant from
Pfizer, Inc.

Related Content

Downloadable slideset with highlights from key hematologic cancers as presented at EHA 2022 Congress, from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 30, 2022

Experts discuss important new data from ASCO 2022 that may impact treatment for chronic lymphocytic leukemia and mantle cell lymphoma, from Clinical Care Options (CCO)

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: June 30, 2022

Downloadable clinical resource with practical guidance on how to talk with your transgender patients about gender identity, including related terminology, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 30, 2022

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care

Jesús G. Berdeja, MD Caron A. Jacobson, MD Released: June 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings